# Technology Appraisal Committee Meeting [Committee D]

**Manchester**

**Minutes: Confirmed**

**Date and Time:** Tuesday 7 January 2020

## Present:

1. Professor Gary McVeigh [Chair] Present for all notes

2. Dr Lindsay Smith [Vice Chair] Present for all notes

3. James Avery Present for all notes

4. Carlo Berti Present for notes 12 to 16

5. Dr David Bowen Present for all notes

6. Matt Bradley Present for notes 7 to 16

7. Sofia Dias Present for all notes

8. Professor Rachel Elliott Present for all notes

9. Gillian Ells Present for all notes

10. David Forman Present for all notes

11. Rebecca Harmston Present for all notes

12. Dr Andrew Hitchings Present for all notes

13. Dr Bernard Khoo Present for all notes

14. Dr Soo Fon Lim Present for all notes

15. Dr Guy Makin Present for all notes

16. Amanda Matse-Orere Present for notes 12 to 21

17. Professor David Meads Present for all notes

18. Olaolu Oloyede Present for all notes

19. Malcolm Oswald Present for all notes

## In attendance:

Ismahan Abdullah Administrator, NICE, Present for notes 12 to 21

Nigel Armstrong Evidence Review Group representative, Kleijnen Systematic Review Present for notes 12 to 13

Max Barnish Evidence Review Group representative, PenTAG Present for notes 17 to 18

Lucy Beggs, Technical Advisor, NICE, Present for notes 12 to 16

Fiona Blackhall, Clinical Expert, nominated by Royal College of Physicians, Present for notes 7 to 8

Ailsa Bosworth, Patient Expert, nominated by NRAS, Present for notes 17 to 18

Rebecca Bouch, Administrator, NICE, Present for notes 1 to 11

Miriam Brazzelli, Evidence Review Group representative, Aberdeen HTA Group, Present for notes 7 to 8

Luke Cowie, Technical Analyst, National Institute for Health and Care Excellence Present for notes 7 to 8

Ewen Cummins, Evidence Review Group representative, PenTAG, Present for notes 17 to 18

Richard Diaz Technical Adviser, NICE, Present for notes 7 to 8

Christopher Edwards, Clinical Expert, nominated by AbbVie, Present for notes 17 to 18

Joanne Ekeledo, Project Manager, NICE, Present for notes 12 to 21

Jamie Elvidge, Technical Advisor, NICE, Present for notes 17 to 21

Alistair Greystoke, Clinical Expert, nominated by Pfizer, Present for notes 7 to 8

Jasdeep Hayre, Associate Director, NICE, Present for notes 12 to 21

Helen Knight Programme Director, NICE, Present for all notes

Linda Landells, Associate Director, NICE, Present for notes 1 to 11

Hamish McAllister-Williams, Clinical Expert, nominated by Janssen Present for notes 12 to 13

G.J. Melendez-Torres, Evidence Review Group representative, PenTAG, Present for notes 17 to 18

Debra Montague, Patient Expert nominated by ALK Positive UK, Present for notes 7 to 8

Alan Moore, Technical Analyst, NICE, Present for notes 17 to 21

Kate Moore, Project Manager, NICE, Present for notes 1 to 11

Omar Moreea, Technical Analyst, NICE, Present for notes 12 to 16

Peter Pratt, NHS Commissioning Expert, Present for notes 12 to 13

Patient Expert, nominated by SANE Present for notes 12 to 13

Graham Scotland Evidence Review Group representative, Aberdeen HTA Group, Present for notes 7 to 8

Robert Wolff Evidence Review Group representative, Kleijnen Systematic Review, Present for notes 12 to 13

**Non-public attendees:**

Emiline Coventry, Editor, NICE, Present for notes 12 to 21

Ann Greenwood, Editor, NICE, Present for notes 1 to 11

Olivia Havercroft, Editor, NICE, Present for notes 7 to 11

Hannah Nicholas, Technical Analyst, NICE, Present for all notes

Susie Roberts, Public Health Registrar, Quality and Leadership, NICE, Present for notes all notes

Hannah Stockton Assistant Technical Analyst, NICE, Present for notes all notes

Maroulla Whiteley Resource Impact Assessment, NICE, Present for notes all notes

Erin Whittingham PIP, NICE, Present for notes all notes

**Notes**

**Any other Business**

1. None.

## Appraisal of Osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302]

### Part 1 – Open session

1. The Chair welcomed the invited representatives from AstraZeneca.
2. The Chair asked all committee members and NICE staff present to declare any relevant interests.
   1. Matt Bradley declared a direct financial interest as he holds shares in a comparator company.
      1. It was agreed that this declaration would prevent Matt Bradley from participating in this section of the meeting.
   2. Amanda Matse-Orere declared a direct financial interest as she works for a comparator company.
      1. It was agreed that this declaration would prevent Amanda Matse-Orere from participating in this section of the meeting.
   3. No further conflicts of interest were declared for this appraisal.

### Part 2 – Closed session [company representatives and members of the public were asked to leave the meeting]

1. Agreement on the content of the Final Appraisal Determination [FAD] was discussed by the committee.
2. The committee decision was based on consensus.

1. The committee asked the NICE technical team to prepare the Final Appraisal Determination [FAD] in line with their decisions.

## Appraisal of Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer [ID1338]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group [ERG] representatives and representatives from Pfizer.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.
   1. Amanda Matse-Orere declared a direct financial interest as she works for a comparator company.
      1. It was agreed that this declaration would prevent Amanda Matse-Orere from participating in this section of the meeting.
   2. No further conflicts of interest were declared for this appraisal.

### Part 2 – Closed session [company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting]

1. Agreement on the content of the Appraisal Consultation Document [ACD] was discussed by the committee.
2. The committee decision was based on consensus.

1. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] in line with their decisions.

## Appraisal of Esketamine for treatment-resistant depression [ID1414]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group [ERG] representatives and representatives from Janssen.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests  
   1. David Meads declared an indirect financial interest as part of his team has received research funding from the company to conduct a trial in haematology.
      1. It was agreed that this declaration would not prevent David Meads from participating in this section of the meeting.
   2. Hamish McAllister-Williams declared a direct financial interest as his team has received fees for consultancy from Janssen and given talks at Janssen Ad Board for esketamine. Hamish McAllister-Williams also declared a direct non-financial interest as he is recruiting participants to two commercial studies funded by COMPASS pathways and LivaNova.
      1. It was agreed that this declaration would prevent Hamish McAllister-Williams from participating in this section of the meeting.
   3. No further conflicts of interest were declared for this appraisal.

### Part 2 – Closed session [company representatives, clinical and patient experts, ERG and members of the public were asked to leave the meeting]

1. Agreement on the content of the Appraisal Consultation Document [ACD] was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] in line with their decisions.

## Appraisal of Upadacitinib for previously treated moderate to severe active rheumatoid arthritis [ID1400]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group [ERG] representatives and representatives from AbbVie.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests  
   1. David Meads declared an indirect financial interest as part of his team has received research funding from the company to conduct a trial in haematology
      1. It was agreed that this declaration would not prevent David Meads from participating in this section of the meeting.
   2. Christopher Edwards declared a direct financial interest as he has received honoraria for attending advisory boards, speaker’s bureau and received research support from companies including AbbVie.
      1. It was agreed that this declaration would prevent Christopher Edwards from participating in this section of the meeting.
   3. Matt Bradley was absent from the meeting due to direct non-financial interest as his company has a medicine in Phase 3 development for rheumatoid arthritis that could be a potential competitor to upadacitinib in the future.
   4. No further conflicts of interest were declared for this appraisal.

### Part 2 – Closed session [company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting]

1. Agreement on the content of the Appraisal Consultation Document [ACD] was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] in line with their decisions.